Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer

被引:23
|
作者
Sun, Xiaoxiang [1 ]
Tang, Huanyin [1 ]
Chen, Yu [1 ]
Chen, Zhixi [1 ]
Hu, Zhiyi [2 ]
Cui, Zhen [1 ]
Tao, Yaming [1 ]
Yuan, Jian [2 ]
Fu, Yun [2 ]
Zhuang, Zhigang [2 ]
He, Qizhi [2 ]
Li, Qian [2 ]
Xu, Xianghong [2 ]
Wan, Xiaoping [1 ,2 ]
Jiang, Ying [1 ,3 ]
Mao, Zhiyong [1 ,2 ,3 ,4 ]
机构
[1] Tongji Univ, Infant Hosp,Sch Life Sci & Technol, Clin & Translat Res Ctr Shanghai Matern & Infant H, Frontier Sci Ctr Stem Cell Res,Shanghai Key Lab Ma, Shanghai, Peoples R China
[2] Tongji Univ, Shanghai Matern & Infant Hosp 1, Shanghai Key Lab Maternal Fetal Med, Sch Med, Shanghai, Peoples R China
[3] Tongji Univ, Sch Life Sci & Technol, Shanghai Key Lab Signaling & Dis Res, Shanghai, Peoples R China
[4] Tongji Univ, Tsingtao Adv Res Inst, Qingdao, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; REPAIR; PROTEIN; EXPRESSION; RESISTANCE; OLAPARIB; THERAPY; STRESS; LIGASE;
D O I
10.1038/s43018-023-00535-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sun et al. identify the deubiquitinase USP15 as a regulator of PARP1 stability in triple-negative breast cancer and show that the hormone receptors ER, PR and HER2 inhibit USP15-mediated PARP1 stabilization, modulating base excision repair. Poly(ADP-ribose) polymerase 1 (PARP1) is essential for the progression of several types of cancers. However, whether and how PARP1 is stabilized to promote genomic stability in triple-negative breast cancer (TNBC) remains unknown. Here, we demonstrated that the deubiquitinase USP15 interacts with and deubiquitinates PARP1 to promote its stability, thereby stimulating DNA repair, genomic stability and TNBC cell proliferation. Two PARP1 mutations found in individuals with breast cancer (E90K and S104R) enhanced the PARP1-USP15 interaction and suppressed PARP1 ubiquitination, thereby elevating the protein level of PARP1. Importantly, we found that estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) inhibited USP15-mediated PARP1 stabilization through different mechanisms. ER bound to the USP15 promoter to suppress its expression, PR suppressed the deubiquitinase activity of USP15, and HER2 abrogated the PARP1-USP15 interaction. The specific absence of these three receptors in TNBC results in high PARP1 levels, leading to increases in base excision repair and female TNBC cell survival.
引用
收藏
页码:716 / +
页数:35
相关论文
共 50 条
  • [21] HER2 Expression in Triple-Negative Breast Cancer: Clinicopathologic Features and Response to Neoadjuvant Chemotherapy
    Morante, Zaida
    Otoya, Iris
    Valdivieso, Natalia
    Calle, Cindy
    Fuentes, Hugo
    Neciosup, Silvia
    Castaneda, Carlos
    Vidaurre, Tatiana
    Falla, Martin
    Colomo, Valeria
    Gomez, Henry
    CANCER RESEARCH, 2024, 84 (09)
  • [22] Nuclear localization of NRF2 in stroma of HER2 positive and triple-negative breast cancer
    Oresic, Tomislav
    Bubanovic, Sanda
    Ramic, Snjezana
    Sarcevic, Bozena
    Gasparovic, Ana Cipak
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 248
  • [23] MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells
    Zeng, Xiaoqi
    Jiang, Shanshan
    Ruan, Simin
    Guo, Zhaoze
    Guo, Jingyun
    Liu, Minfeng
    Ye, Changsheng
    Dong, Jianyu
    MOLECULAR MEDICINE REPORTS, 2021, 24 (02)
  • [24] PARP1, BRCA1 and androgen receptor expression in triple-negative breast cancer patients treated with neoadjuvant chemotherapy
    Rashed, Hayam E.
    Monged, Randa E.
    Nawar, Nashwa
    Alattar, Ahmed Z.
    Alnagar, Ahmed A.
    Abdelhamid, Mohamed I.
    Abdelaziz, Osama
    Said, Nelly M.
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2022, 35 (04): : 228 - 235
  • [25] How should we best target the biology of ER PR HER2 negative breast cancer?
    Tutt, A. N. J.
    Reis-Filho, J. S.
    EJC SUPPLEMENTS, 2008, 6 (07): : 166 - 166
  • [26] USP1-mediated deubiquitination of KDM1A promotes the malignant progression of triple-negative breast cancer
    Su, Yang
    Du, Yan
    He, Wenguang
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2024, 38 (10)
  • [27] Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results
    Nakagawa, Misako
    Bando, Yoshimi
    Nagao, Taeko
    Takai, Chikako
    Ohnishi, Takamasa
    Honda, Junko
    Moriya, Takuya
    Izumi, Keisuke
    Takahashi, Masako
    Tangoku, Akira
    Sasa, Mitsunori
    BREAST CANCER, 2012, 19 (01) : 54 - 59
  • [28] EFFECT OF HER2 OVEREXPRESSION ON CANCER STEM-LIKE CHARACTERISTICS OF TRIPLE-NEGATIVE BREAST CANCER CELLS
    Hosonaga, M.
    Arima, Y.
    Kohno, N.
    Ishikawa, T.
    Saya, H.
    ANNALS OF ONCOLOGY, 2014, 25
  • [29] Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results
    Misako Nakagawa
    Yoshimi Bando
    Taeko Nagao
    Chikako Takai
    Takamasa Ohnishi
    Junko Honda
    Takuya Moriya
    Keisuke Izumi
    Masako Takahashi
    Akira Tangoku
    Mitsunori Sasa
    Breast Cancer, 2012, 19 : 54 - 59
  • [30] Response to neoadjuvant chemotherapy among women with triple-negative breast cancer by HER2 expression status
    Budhathoki, Pravash
    Shah, Anish
    Gaire, Suman
    Joshi, Utsav
    Yadav, Siddhartha
    CANCER RESEARCH, 2023, 83 (05)